Drug Information Analysis Service

Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. MMWR Morb Mortal Wkly Rep 1987; 36 (1S suppl):3S–14S.

Nahlen BL Chu SY Nwanyanwu OC Berkelman RL Martinez SA Rullan JV . HIV wasting syndrome in the United States. AIDS 1993; 7: 183–8.

Kotler DP Tierney AR Wang J Pierson RN Jr . Magnitude of body-cell-mass depletion and the timing of death from wasting in AIDS. Am J Clin Nutr 1989; 50: 444–7.

Grunfeld C Kotler DP . Pathophysiology of the AIDS wasting syndrome. AIDS Clin Rev 1992; 191–224.

Hickey MS . Nutritional support of patients with AIDS. Surg Clin North Am 1991; 71: 645–64.

Jones WN . Task Force on Nutrition in AIDS. Update: October 1989 guidelines for nutrition support in AIDS. J Arkansas Med Soc 1989; 86: 219–28.

Plasse TF Gorter RW Krasnow SH Lane M Shepard KV Wadleigh RG . Recent clinical experience with dronabinol. Pharmacol Biochem Behav 1991; 40: 695–700.

Gorter R Seefried M Volberding P . Dronabinol effects on weight in patients with HIV infection. AIDS 1992; 6: 127–38.

Food and Drug Administration. Unimed's Marinol (dronabinol) gains indication for anorexia in AIDS patients. FDC Rep 1993;Jan 4:14.

Von Roenn JH Murphy RL Wegener N . Megestrol acetate for treatment of anorexia and cachexia associated with human immunodeficiency virus infection. Sem Oncol 1990; 17 (suppl 9):13–6.

Von Roenn JH Murphy RL Weber KM Williams LM Weitzman SA . Megestrol acetate for treatment of cachexia associated with human immunodeficiency virus (HIV) infection. Ann Intern Med 1988; 109: 840–1.

Hellerstein MK Kahn J Mudie H Viteri F . Current approach to the treatment of human immunodeficiency virus-associated weight loss: Pathophysiologic considerations and emerging management strategies. Sem Oncol 1990; 17: 17–33.

Food and Drug Administration. Bristol-Myers Squibb's megace for AIDS-related weight loss recommended for approval in split vote; mortality, use in women questioned by advisory cmte. FDC Rep 1993;Feb 22:13–4.

Mahayni H Minor JR . Megestrol acetate in AIDS-related cachexia. AJHP 1991; 48: 2479–80.

Henry K Rathgaber S Sullivan C McCabe K . Diabetes mellitus induced by megestrol acetate in a patient with AIDS and cachexia. Ann Intern Med 1992; 116: 53–4.

Nathwani D Green ST Heslop JM Goldberg DJ Kennedy DH . Beneficial response to megoestrol acetate in AIDS-related cachexia and a possible megoestrol withdrawal-associated syndrome?. Acta Derm Venereol 1990; 70: 520–1.

Kotier DP Tierney AR Ferraro R Cuff P Wang J Pierson RN . Enteral alimentation and repletion of body cell mass in malnourished patients with acquired immunodeficiency syndrome. Am J Clin Nutr 1991; 53: 149–54.

Yarchoan R Weinhold KJ Lyerly HK Gelmann E Blum RM Shearer GM . Administration of 3′-azido-3′-deoxythymidine, an inhibitor of HTLV-III/LAV replication, to patients with AIDS or AIDS-related complex. Lancet 1986; 1: 575–80.

McEvoy GK , ed. American Hospital Formulary Service drug information 93. Bethesda, MD: American Society of Hospital Pharmacists, 1993.

Lambert JS Seidlin M Reichman RC Plank CS Laverty M Morse GD . 2′,3′-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. A phase I trial. N Engl J Med 1990; 322: 1333–40.

Rubin W . Medical treatment of peptic ulcer disease. Med Clin North Am 1991; 75: 981–8.

Tytgat GNJ . Drug therapy of reflux oesophagitis: An update. Scand J Gastroenterol 1989; 26 (suppl 168):38–49.

Kitchin LI Castell DO . Rationale and efficacy of conservative therapy for gastroesophageal reflux disease. Arch Intern Med 1991; 151: 448–54.

Lacz JP Drees DT Browne RK . Sucralfate binding in Cimetidine treated rats. Gastroenterology 1983; 84: 1220.

Schotborgh RH Hameeteman W Dekker W Boomgaard DM van Olffen GH Schrijver M . Combination therapy of sucralfate and Cimetidine, compared with sucralfate monotherapy, in patients with peptic reflux esophagitis. Am J Med 1989; 86 (suppl 6A):77–80.

Vermeijden JR Tytgat NJ Schotborgh R Dekker W Boomgaard DM van Olffen GH . Combination therapy of sucralfate and ranitidine, compared with sucralfate monotherapy, in patients with peptic reflux esophagitis. Scand J Gastroenterol 1992; 27: 81–4.

Herrera JL Shay SS McCabe M Peura DA Johnson LF . Sucralfate used as adjunctive therapy in patients with severe erosive peptic esophagitis resulting from gastroesophageal reflux. Am J Gastroenterol 1990; 85: 1335–8.

Package insert. Tagamet (Cimetidine). Philadelphia: SmithKJine Beecham Pharmaceuticals, February 1993.

Package insert. Zantac (ranitidine). Research Triangle Park, NC: Glaxo Pharmaceuticals, May 1992.

Alacz JP Browne RK Drees DT . Effects of antacid therapy on the binding of sucralfate to gastric ulcers in the rat(abstract). Gastroenterology 1983; 84: 1220.

Van Deventer GM Schneidman D Walsh JH . Sucralfate and Cimetidine as single agents and in combination for treatment of active duodenal ulcers. Am J Med 1985; 79 (suppl 2C):39–44.

Houston LJ Mills JG Wood JR . Does co-prescription of sucralfate with ranitidine therapy enhance the healing of gastric ulcers?. Am J Gastroenterol 1993; 88: 675–9.

Takemoto T Kimura K Okita K Tsuneoka K Ohshiba S Namiki M . Efficacy of sucralfate in the prevention of recurrence of peptic ulcer—double blind multicenter study with Cimetidine. Scand J Gastroenterol 1987; 22 (suppl 140):49–60.

Kane MP Briceland L Garris R Favreau B . Drug-use review program for concurrent histamine H₂-receptor antagonist-sucralfate therapy. Am J Hosp Pharm 1990; 47: 2007–10.

Porro GB Pace F Peracchia A Bonavina L Vigneri S Scialabba A . Short-term treatment of refractory reflux esophagitis with different doses of omeprazole or ranitidine. J Clin Gastroenterol 1992; 15: 192–8.

Mogabgab MJ . Recent developments in the treatment of sexually transmitted diseases. Am J Med 1991; 91 (suppl 6A):140s–4s.

Division of Sexually Transmitted Diseases/HIV prevention. Sexually transmitted disease surveillance 1991 report. Atlanta: Centers for Disease Control, 1991.

Kassler WJ Cates W Jr . The epidemiology and prevention of sexually transmitted diseases. Urol Clin North Am 1992; 19: 1–12.

Zenilman JM . Update on bacterial sexually transmitted disease. Urol Clin North Am 1992; 19: 25–8.

Centers for Disease Control: CDC: Division of Sexually Transmitted Diseases, US Department of Health and Human Services. 1989 Sexually transmitted diseases treatment guidelines. MMWR Morh Mortal Wkly Rep 1989; 38: 1–43.

Centers for Disease Control. CDC: Division of Sexually Transmitted Diseases, US Department of Health and Human Services. 1993 Sexually transmitted diseases treatment guidelines. MMWR Morb Mortal Wkly Rep 1993; 42: 56–60.

Handsfield H McCormak WM Hook EW Douglas JM Covino JM Verdon MS . A comparison of single-dose Cefixime with ceftriaxone as a treatment for uncomplicated gonorrhea. N Engl J Med 1991; 325: 1337–41.

Portilla I Lutz B Montalvo M Mogabgab WJ . Oral Cefixime versus intramuscular ceftriaxone in patients with uncomplicated gonococcal infections. Sex Transm Dis 1992; 19: 94–8.

Rodriguez A Rivcra-Castano R Garcia H Garcia M Galindez SI Torres-Bauza LJ . Oral Cefpodoxime versus ceftriaxone in the treatment of uncomplicated gonorrhea (abstract 1324). 13th Interscience Conference of Antimicrob Agents Chemother, Atlanta, GA, October 1990.

Hooper DC Wolfson JS . Treatment of genitourinary tract infections with fluoroquinolones: Clinical efficacy in genital infections and adverse effects. Antimicrob Agents Chemother 1989; 22: 1662–7.

Hooton TM Batteiger BE Judson FN Spruance SL Stamm WE . Ofloxacin versus doxycycline for treatment of cervical infection with chlamydia trachomatis. Antimicrob Agents Chemother 1992; 36: 1144–6.

Covino JM Cummings M Smith B Benes S Draft K McCormack WM . Comparison of ofloxacin and ceftriaxone in the treatment of uncomplicated gonorrhea caused by penicillinase-producing and non-penicillinase-producing strains. Antimicrob Agents Chemother 1990; 34: 148–9.

Roddy RE Handsfield HH Hook EW . Comparative trial of single-dose ciprofloxacin and ampicillin plus probenecid for treatment of gonococcal urethritis in men. Antimicrob Agents Chemother 1986; 30: 267–9.

Hook EW III Jones RB Martin DH Bolan GA Mroczkowski TF Neumann TM . Comparison of ciprofloxacin and ceftriaxone as single-dose therapy for uncomplicated gonorrhea in women. Antimicrob Agents Chemother 1993; 37: 1670–3.

Martin DH Mroczkowski TF Dalu AZ McCarty J Jones RB Hopkins SJ . A controlled trial of single dose of azithromycin for the treatment of chlamydial urethritis and cervicitis. N Engl J Med 1992; 327: 921–5.

Lassus A . Comparative studies of azithromycin in skin and soft-tissue infections and sexually transmitted infections by Neisseria and Chlamydia species. J Antimicrob Chemother 1990; 25 (suppl A): 115–21.

Wyler DJ . Malaria: Overview and update. Clin Infect Dis 1993; 16: 449–58.

Wyler DJ . Bark, weeds, and iron chelators—drugs for malaria. N Engl J Med 1992: 327: 1519–21.

Masawe AEJ Muindi JM Swai GRB . Infection in iron deficiency and other types of anaemia in the tropics. Lancet 1974; 2: 314–7.

Raventos-Suarez C Nagel RL . Plasmodium falciparum: Inhibition of in vitro growth by desferrioxamine. Am J Trop Med Hyg 1982; 31: 919–22.

Balcerzak SP Westerman MP Heinle EW Taylor FH . Measurement of iron stores using deferoxamine. Ann Intern Med 1968; 68: 518–25.

Hershko C Peto TEA . Deferoxamine inhibition of malaria is independent of host iron status. J Exp Med 1988; 168: 375–8.

Harvey PWJ Heywood PF Nesheim MC Galme K Zegans M Habicht JP . The effect of iron therapy on malarial infection in Papua New Guinean school children. Am J Trop Med Hyg 1989; 40: 12–8.

Traore O Carnevale P Kaptue-Noche L M'Bede J Desfontaine M Elion J . Preliminary report on the use of desferrioxamine in the treatment of Plasmodium falciparum malaria. Am J Hematol 1991; 37: 206–8.

Bunnag D Poltera AA Vifavan C Looareesuwan S Harinasuta KT Schindlery C . Plasmodicidal effect of desferrioxamine B in human vivax or falciparum malaria from Thailand. Acta Tropica 1992; 52: 59–67.

Gordeuk VR Thuma PE Brittenham GM Zulu S Simwanza G Mhangu A . Iron chelation with desferrioxamine B in adults with asymptomatic Plasmodium falciparum parasitemia. Blood 1992; 79: 308–12.

Gordeuk V Thuma P Brittenham G McLaren C Parry D Backenstrose A . Effect of iron chelation therapy on recovery from deep coma in children with cerebral malaria. N Engl J Med 1992; 327: 1473–7.

Gordeuk VR Thuma PE Brittenham GM Biemba G Zulu S Simwanza G . Iron chelation as a chemotherapeutic strategy for Falciparum malaria. Am J Trop Med Hyg 1993; 48: 193–7.

Bjorkman A Phillips-Howard PA . The epidemiology of drug-resistant malaria. Trans R Soc Trop Med Hyg 1990; 84: 177–80.

Yinnon AM Theanacho EN Grady RW Spira DT Hershko C . Antimalarial effect of HBED and other phenolic and catecholic iron chelators (abstract). Blood 1989; 74: 2166.

Clarke CJ Eaton JM . Hydrophobic iron chelators as new antimalarial drugs (abstract). Clin Res 1990; 38: 300A.